Introduction
The relationship of styrene toxicity and cancer has been reviewed previously based on data that did not include more recent updates of the styrene epidemiology cohorts and animal mode of action studies (IARC, 2002; ATSDR, 2010; NAS, 2014) . These recent data can now inform a current assessment of the mouse lung tumor MOA and its quantitative and/or qualitative relevance to human cancer risks.
Background: styrene toxicity and metabolism
1. The only tumorigenic response in rats and mice to styrene exposure is mouse lung tumors.
There are 8 chronic studies of styrene in rats (Table 1 , reviewed in Cruzan et al., 2002) . There are no increases in lung tumors or consistent increases in tumors at other sites. Malignant mammary tumors were increased in one inhalation study in Sprague-Dawley rats (Conti et al., 1988) , but not in a gavage study conducted at similar doses at the same laboratory at the same time in the same strain. No increase in mammary tumors was reported in 3 other gavage studies (F344 or BDIV rats) or 1 drinking water study in S-D rats. Malignant mammary tumors were found at 600 ppm styrene by inhalation (within historical control range), but not at 1000 ppm (Jersey et al., 1978) in S-D rats. No increase in mammary tumors occurred from exposure to 50 or 200 ppm styrene by inhalation in S-D rats (Cruzan et al., 1998) and a dose-related decrease in malignant mammary tumors was found at 500 and 1000 ppm. Mammary tumors are extremely common in rats, especially the S-D strain. Thus the weight of the evidence indicates that styrene does not induce mammary gland tumors.
In contrast to rats, multiple studies in mice indicate that lung is the only cancer target organ following either oral or inhalation exposures. There are 4 long-term gavage studies of styrene in mice and 1 by inhalation (Table 2 ). Oral gavage of 300 mg/kg/day styrene in corn oil 5 days/week for 78 weeks, with additional observation to week 91, resulted in increased lung tumors in male, but not female, B6C3F1 mice https://doi.org/10.1016/j.yrtph.2018.02.010 Received 8 January 2018; Received in revised form 14 February 2018; Accepted 15 February 2018 (NCI, 1979a) . The evidence of lung cancer was considered "Suggestive" by the NCI review panel. Oral gavage of 0, 204, or 408 mg/kg/dose of 30% β-nitrostyrene/70% styrene 3 days/week for 78 weeks with observation to week 91 (styrene dose adjusted to 5 days/week = 0, 122 or 244 mg/kg/day) did not result in increased lung tumors (NCI, 1979b) . When styrene was administered by gavage at 1400 mg/kg/dose on day 17 of gestation and once weekly to offspring of O20 mice, there was severe lung congestion and 50% mortality by week 16, when dosing was stopped. Survivors were observed until week 120. Increased lung tumors compared to solvent controls, but not untreated controls were found (Ponomarkov and Tomatis, 1978) . A similar study of styrene in C56BL/6 mice dosed at 300 mg/kg/dose did not find lung toxicity or tumors (Ponomarkov and Tomatis, 1978) . None of these studies evaluated the development of proliferative lesions during the course of the exposure.
In the inhalation study, there were increased lung tumors in male CD-1 mice at 40, 80 and 160 ppm and at 20, 40, and 160 ppm (not at 80 ppm) in females (6 h/day, 5 days/week, 104 weeks). These were mostly benign and the increase was not seen until after 18 months of exposure (Cruzan et al., 2001) . Tumors in these studies were found in the periphery of the lung, which encompasses areas of terminal bronchioles and alveoli. Because the origin of the tumors cannot be determined by cellular anatomy or location, these are referred to as bronchioloalveolar adenomas or adenocarcinomas.
2. There are species and organ differences in styrene metabolism.
Many metabolites of styrene have been identified in various organs or urine. These can be collated into 4 general pathways: 1. Styrene-7,8-oxide (SO) followed by epoxide hydrolase to mandelic acid; 2. Styrene-7,8-oxide followed by GSH transferases resulting in conjugation and progression to mercapturic acids. 3. Oxidation of vinyl side chain to phenylacetaldehyde (or rearrangement from SO) and further oxidation; and 4. Oxidation of the aromatic ring, with or without vinyl side chain oxidation. Differences in the relative contribution of each pathway exist among rat, mouse and human. The relative contribution of each pathway to urinary metabolites of styrene is shown in Table 3 . .
Styrene metabolism to SO is the primary pathway for removal of styrene from animals, including humans. SO formation is catalyzed primarily by CYP2E1 in all species; however, other CYPs may also be involved, but such alternative CYP-oxidations to SO may be speciesand organ-dependent. For example, in CYP2E1-knockout mice (KO), SO is still produced in liver and lung. Shen et al. (2010) reported a 44% decrease in styrene glycol in liver microsomes of CYP2E1-KO mice compared to wild-type mice and no reduction in lung microsomes. In contrast, they reported a 25% decrease in styrene glycol in microsomes from the livers of CYP2F2-KO mice and a 64% decrease in lung microsomes of the CYP2F2-KO mice. The SO-EH pathway accounts for > 95% of styrene metabolism in humans . The relative roles of CYP2E1 and CYP2F2 in the mouse-specific lung tumor MOA will be discussed later. Ring-oxidized metabolites of styrene include 2-hydroxystyrene, 3-hydroxystyrene, 4-hydroxystyrene (2-, 3-, or 4-vinylphenol), 3,4-dihydroxystyrene (4-vinylphenol catechol) and 4-hydroxystyrene-7,8-oxide (4-(2-oxiranyl)-1, 2-benzenediol) (Shen et al., 2010; Zhang et al., 2011) . There was an > 80% reduction in formation of these metabolites by inhibition of CYP2F2 by 5-phenyl-1-pentyne (5P1P) and complete attenuation of 2-, 3-and 4-vinylphenol formation in lung microsomes from CYP2F2-KO mice (Shen et al., 2014) . The role of ring-oxidized metabolites in the mouse lung tumor MOA will be discussed later.
A framework for analyzing modes of action/human relevance has been proposed and updated (Meek et al., 2013 (Meek et al., , 2014 . The induction of Taken from Cruzan et al. (2002) . Cruzan et al. (2002) .
G. Cruzan et al. Regulatory Toxicology and Pharmacology 95 (2018) 17-28 lung tumors in mice following styrene exposure will be examined using this framework. The framework consists of identifying key events, the consistency, dose-response, concordance among key events, and temporal associations. Key events are the changes necessary for the outcome to happen. Two hypotheses have been put forward to explain these mouse lung tumors: 1. CYP2F2 metabolism to ring-oxidized metabolites and 2. metabolism to styrene-7,8-oxide. Each of these is examined.
Mode of action (MOA) hypotheses
3. CYP2F2 metabolism of styrene to ring-oxidized metabolites leads to changes in gene expression for metabolism of lipids and lipoproteins, cell cycle and mitotic M-M/G1 phases, mild cytotoxicity and strong mitogenicity in the club (Clara) cells in the terminal bronchioles of mice with subsequent changes of club cell circadian controls, leading to excessive cell proliferation, hyperplasia and late in life appearance of lung tumors (Fig. 1 ).
Key events

Key event #1 -molecular initiating event (MIE): lung metabolism by CYP2F2
Based on urinary metabolites, a major difference in the metabolism of styrene between rats and mice is the amount of oxidation of the aromatic ring (up to 8% in mice vs. 0.5% in rats). Using isolated lung cell fractions enriched in club cells or alveolar cells, Carlson and colleagues determined that the metabolism of styrene occurred in club cells and not in alveolar cells (Hynes et al., 1999) . In the club cells, styrene is metabolized by CYP2F2 to ring-oxidized metabolites. One annotated role of CYP2F2 based on biological aspect of ancestor proteins is oxidation of aromatic rings in the formation of steroid hormones (Jackson Labs., 2017) . Styrene metabolites include 2-hydroxystyrene, 3-hydroxystyrene, 4-hydroxystyrene (2-, 3-, or 4-vinylphenol), 3,4-dihydroxystyrene, and 4-hydroxystyrene-7,8-oxide . There is an > 80% reduction in formation of these metabolites by inhibition of CYP2F2 by 5-phenyl-1-pentyne or in CYP2F2-KO mice (Shen et al., 2014) . Loss of CYP2F2 (CYP2F2-KO mice) attenuated the lung toxicity from a single oral dose of styrene, as measured by cells, protein and LDH in broncho-alveolar lavage fluid (Carlson, 2012; Shen et al., 2014) and completely eliminated increased BrdU incorporation resulting from 5 days of oral exposure (Cruzan et al., 2012) . However, styrene-induced lung toxicity was not attenuated in CYP2E1-knockout mice (Carlson, 2004) .
CYP2F2 metabolism also is essential in the induction of long-term repeated-dose styrene lung toxicity, including up to 104-week inhalation exposures to 120 ppm styrene. Styrene-induced toxicity, cell proliferation and/or associated hyperplasia were absent at all times sampled (1, 26, 52, 78 and 104 weeks) in CYP2F2-KO and CYP2F1-TG mice relative to WT controls or CD-1 mice .
The metabolism data indicate that styrene CYP2F2 metabolism in mice is a critical molecular-initiating event required for onset of lung toxicity. In the absence of CYP2F2 activity, or in the presence of the human CYP2F1 isoform, none of the ensuing hypothesized key events are observed. Thus, CYP2F2 metabolism serves a key metabolic gateway to the hypothesized mode of action; if that molecular metabolic gate is closed, toxicity is not observed.
Key event #2 -changes in gene expression in mouse lung
Styrene gene expression has been characterized in mice after exposures of various durations. WT mice were exposed to styrene by inhalation for 6 h 1 day at 0, 1, 5, 10, 20, 40 and 120 ppm or for 6 h/day 5 days/week for 1, 4 or 26 weeks. The 1 and 4-week studies were at 40 and 120 ppm and the 26 weeks at 120 ppm. Five biological replicates for each treatment group of mice were analyzed for relative gene expression using Affymetrix whole genome HT_MG430_PM Titan arrays. There were broad concentration dependent changes in gene expression after 1 day (Table 4) . Pathway enrichment was primarily for metabolism of lipids and lipoproteins, cell cycle and mitotic M-M/G1 phases and DNA repair . The numbers of genes altered G. Cruzan et al. Regulatory Toxicology and Pharmacology 95 (2018) 17-28 using fold-change and false discovery rate criteria at 40 and 120 ppm decreased over time -1087 and 10,213 at 1-day, 512 and 727 at 1 week, 23 and 88 at 4 weeks, and none at 26 weeks (Table 5 ). At 4-and 26-weeks using fold-change criteria alone, key transcription factors (TFs) were up-regulated (Nr1d1, Nr1d2, Dbp, Tef, Hlf, Per3, Per2 and Bhlhe40) and others (Npas, Arntl, Nfil3, Nr4a1, Nr4a2, and Nr4a3) were downregulated with TF gene enrichment for circadian clock and nuclear receptor pathways. Gene expression data indicate that styrene causes immediate mitogenic responses in lungs, likely from ring-oxidized metabolites that are likely activating Nr4a signaling (Tables 4 and 5 ).
Longer-term responses include down-regulation of these Nr4a genes and shifts in circadian clock genes and D-box genes linking circadian signaling to cellular metabolism. The enrichment of the DNA-repair pathways is associated with surveillance of DNA integrity during proliferation rather than with any intrinsic production of reactive metabolites from styrene. There were increases in DNA-repair processes during the first week after which the gene expression patterns changed considerably with no contribution from DNA-repair pathway enrichment at 4 or 26 weeks, i.e., these patterns of DNA-repair enrichment occurred along with those for mitotic signaling. Gene expression responses in mouse lung across various exposure durations are consistent with a non-genotoxic, primarily mitogenic MOA for styrene in mouse lungs with no evidence for stress-pathway responses to reactive metabolites or activation of p53-mediated DNA-damage pathways. No enhancement of gene expression was found in CYP2F2-KO mice (Tables 4 and 5 ).
There were no changes in gene expression at any of the time points examined and no evidence of histopathological changes or proliferation at the short or longer times in either the CYP2F2-KO or CYP2F1-TG mice. In addition, these strains did not show as consistent a pattern of downregulation of the Nr4a family group of receptors as seen at the longer times with the WT (C57BL/6) mice. The CYP2F2-KO mice had some TF responses at 120 ppm and the CYP2F1-TG mouse response was even more muted.
The genomic data affirm the critical gateway of CYP2F2 metabolism in styrene-mediated mouse lung toxicity and tumorigenicity. The extensive hepatic and lung metabolism of styrene by CYP2E1 to SO does not appear to contribute to lung toxicity given the total absence of styrene-induced responses in CYP2F2 KO mice, even though CYP2F2 KO and WT mice expressed equivalent levels of CYP2E1 in liver and lung (Li et al., 2011) and overall liver and lung microsomal metabolism of styrene to the primary metabolite of SO, styrene glycol, was reduced by 25 and 64%, respectively (Shen et al., 2014) .
Key event #3 -cytotoxicity and mitogenesis in bronchiolar cells
A single oral or ip dose of 600 mg/kg/day to mice resulted in increased cells recovered from broncho-alveolar lavage fluid (BALF), presumably exfoliated club cells, as well as increased protein and LDH (Gadberry et al., 1996; Carlson, 1997) . Shen et al. (2014) also reported increased cells counts and LDH activity in BALF in mice administered a single dose of 625 mg/kg ip styrene. Mild degeneration of club cells was found at the end of a single 6 h inhalation of 40 or 160 ppm styrene in mice, but was absent after 18 h of recovery (Green et al., 2001 ). However, minimal to mild degeneration, necrosis, exfoliation and/or attenuation of bronchiolar epithelium was noted in C57BL/6 mice (WT strain for CYPF2-KO) 18 h after single 10, 40 or 120 ppm 6 h styrene exposures . Only mild degeneration of club cells was found following 1-104 weeks of inhalation of 120 ppm styrene in CD-1 or C57BL/6 (WT) mice . These observations (LDH release into BAL fluid, release of cells in the airways and histological changes in the tissue) are referred to as "toxicity" in this paper. Styrene toxicity, as described above, is found only in club cells, located primarily in the terminal bronchioles, but can affect the club cells found higher up in the respiratory tree . No toxicity has been found in the alveoli (Cruzan et al., 1997 (Cruzan et al., , 2001 , 2012 2017) .
Styrene significantly increased CD-1 mouse club cell proliferation as measured by BrdU incorporation by 2.8-and 3.6-fold, respectively, following 2 weeks of exposure to 150 and 200 ppm; increased proliferation was not observed in club cells after 5 and 13 weeks of treatment or in Type II pneumocytes at 2, 5 and 13 weeks (Cruzan et al., 1997) . Mice dosed orally with 200 mg/kg/day styrene 5 days/week for 1-13 weeks had increased cell replication as measured by BrdU incorporation into the cells of the terminal bronchioles (Cruzan et al., 2012 (Cruzan et al., , 2015 . Typical results after 5 days of exposure are found in Table 6 . Increased cell replication, as measured by KI-67, also was found after 1 week of inhalation of 120 ppm styrene, but not after 26, 52, or 78 weeks of exposure . No increase in cell replication (measured by BrdU or KI-67) occurred in CYP2F2-KO or CYP2F1-TG mice administered styrene orally or by inhalation (Cruzan et al., 2012 . Increased cell proliferation could be reparative or mitogenic in nature; the stimulus cannot be determined from the response. However, based on the gene expression data, the proliferation is driven more by a mitogenic stimulus than a reparative one in the lungs of styrene-exposed mice.
In short-term studies 4-hydroxystyrene (4HS, also referred to as 4-vinylphenol) is toxic to mouse lung at lower doses than styrene or SO 
Two studies were conducted in separate laboratories. Criteria = statistically significant (p < 0.05) and difference > 1.5-fold expression in control mice of same strain. WT = wild type mice; KO = CYP2F2 (−/−) mice; TG = CYP2F2(−/−) (2F1, 2A5, 2B6 transgene). Taken from Andersen et al. (2018) . G. Cruzan et al. Regulatory Toxicology and Pharmacology 95 (2018) 17-28 . At 100 mg/kg, no lung toxicity (measured as cellular debris and LDH in BALF) was found from styrene, SO, 2-hydroxystyrene, or 3-hydroxystyrene, but 4-hydroxystyrene produced lung toxicity (Shen et al., 2010) . In a 2-week study, the NOAEL for lung toxicity from 4HS was 2 mg/kg/day (Cruzan et al., 2005) compared to 70 mg/kg/day for styrene (50 ppm 6 h/day) (Cruzan et al., 1997) .
In a 5-day study, administration of 60 or 105 mg/kg/day 4HS caused increased cell replication as measured by incorporation of BrdU in terminal bronchiolar cells of C57BL/6 mice (Cruzan et al., 2013) . Some increased BrdU incorporation was present at 105 mg/kg/day even in the absence of CYP2F2 metabolism (Table 6) .
No increased BrdU incorporation was found in Sprague-Dawley rats exposed to 200-1500 ppm styrene 6 h/day 5 days/week for up to 13 weeks (Cruzan et al., 1997) . No degeneration of club cells was found in the lungs of rats exposed to 50-1000 ppm styrene 6 h/day 5 days/week for up to 104 weeks (Cruzan et al., 1998) . No lung toxicity or increased cell replication has been found from the administration of SO or 4HS in rats (Cruzan et al., 2005) .
Key event 3 is driven primarily by mitogenicity (stimulation of cell proliferation by ring-oxidized metabolites) with the possibility of weak cytotoxicity as evidenced by increased cell debris and enzyme biomarkers in lung lavage fluids. In contrast to gene expression changes and increased cell proliferation/hyperplasia consistent with enhanced mitogenicity of styrene, no gene expression changes were indicative of cytotoxicity. A similar CYP2F2-metabolite driven mitogenic MOA has been postulated for the mouse lung specific toxicity of the pesticide fluensulfone and anti-tubercular drug isoniazid (Strupp et al., 2012 (Strupp et al., , 2016 . . Isoniazid is an interesting and important comparator example relative the hypothesized CYP2F2 mode of action for styrene and fluensulfone because it has been used for more than 60 years at doses similar to those that cause increased lung tumors in mice. IARC has summarized the epidemiologic data on patients treated with isoniazid, which shows no increased risk of lung tumors or other cancers in patients treated with isoniazid (IARC, 1985 (IARC, , 1987 .
Key event #4
-preneoplastic hyperplasia with progression to tumors from styrene exposure Two gavage studies reported suggestive evidence of increased lung tumors in mice from styrene exposure, while two other gavage studies found no evidence of an increase ( Table 2) . None of these studies evaluated the development of proliferative lesions during the course of the exposure.
Inhalation exposure to styrene at 40 ppm resulted in hyperplasia in the terminal bronchioles of a few CD-1 mice after 52 weeks; by 104 (males) or 98 (females) weeks, nearly all exposed mice had hyperplasia in the terminal bronchioles, which extended into the alveolar ducts. At 80 and 120 ppm, a greater percentage of mice had hyperplasia at 12 months (Cruzan et al., 2001) . Styrene exposure at 40, 80 and 160 ppm induced lung tumors in male CD-1 mice and at 20, 40 and 160 ppm in female CD-1 mice (Cruzan et al., 2001 ). Tumors were not increased at any other site in these mice.
A chronic mode of action study was conducted to assess the role of styrene CYP2F-mediated metabolites in the formation of proliferative alterations and potential tumorigenicity in mouse lung. Styrene was administered by inhalation at 120 ppm 6 h/day 5 day/week for 104 weeks to male CD-1, WT (C57BL/6), CYP2F2-KO, and CYP2F1 humanized TG mice. After 1, 26, 52, 78, or 104 weeks, proliferative alterations were observed in the terminal bronchioles of CD-1 and WT mice; overall proliferative alterations were found in 58 of 67 styrene-exposed CD-1 and 55 of 70 WT mice (Table 7) . No proliferative lesions were found in any of the 69 KO mice or 68 humanized mice . The incidence of styrene bronchiolar adenomas in CD-1 mice was not altered by 120 ppm styrene (15/67 controls; 14/67 styrene), but bronchiolar adenocarcinomas were non-significantly increased (7/ 67 controls; 17/67 styrene). The incidence of adenomas and adenocarcinomas was comparatively lower in control WT mice (3 and 0/69), and lung adenomas and adenocarcinomas in KO and TG were not altered by styrene (KO control: 0 and 2/69; KO styrene: 0 and 0/69; TG control: 2 and 1/69; TG styrene: 1 and 0/68, respectively). Despite the absence of styrene-induced tumors in WT mice, these mice exhibited terminal bronchiole preneoplastic hyperplasia similar to that noted in CD-1 mice, and which was not observed in KO or TG mice. Inhalation exposure to 50, 200, 500 or 1000 ppm styrene 6 h/day 5 days/week for 104 weeks did not result in hyperplasia or increased lung tumors in Sprague-Dawley rats, or any other type of tumors (Cruzan et al., 1998) .
Concordance of dose-response relationships between key and end events
In the absence of CYP2F2 metabolism (i.e., in CYP2F2-KO mice), no subsequent early or late key events are observed (toxicity, cell proliferation, gene changes, hyperplasia or tumors), regardless of dose. That is, metabolism of styrene by CYP2F2 is a gate for subsequent events. When the gate is closed (no CYP2F2 metabolism), there are no subsequent events.
Hyperplasia was found in the terminal bronchioles of CD-1 mice exposed to 20 ppm or greater styrene 6 h/day 5 days/week for up to 104 weeks (Cruzan et al., 2001) . Lung tumors were significantly increased in male CD-1 mice at 40, 80 and 160 ppm, and in females at 20, 40, (not 80) and 160 ppm. Increased hyperplasia was also observed in CD-1 and WT mice treated up to 104 weeks with 120 ppm styrene . Increased cell proliferation, as measured by BrdU incorporation or KI-67 production in CD-1 mice, has been reported at exposures of 40,120, and 160 ppm styrene (Green et al., 2001; Andersen et al., 2017) . Increased cell proliferation has also been reported for C57BL/6 mice (WT) at 40 ppm or greater by inhalation or 200 mg/kg/day by gavage or ip administration for 5 days (Cruzan et al., 2012 (Cruzan et al., , 2013 . Cell proliferation (KI-67) also was increased at 1 week, but not after 26, 52, and 78 weeks of exposure to 120 ppm in CD-1 and WT mice in the mode of action bioassay .
Enhanced gene expression occurred from a 6-h inhalation exposure to 5 ppm or greater in WT mice. Enhanced gene expression continued through 4 weeks of exposure at 40 or 120 ppm . No enhanced gene expression was found from 1 day through 26 weeks of inhalation exposure to styrene at up to 120 ppm in CYP2F2-KO mice.
Metabolism of styrene by CYP2F2 has been demonstrated by measuring ring-oxidized metabolites Shen et al., 2014) . Production of ring-oxidized metabolites was reduced by inhibiting CYP2F2 with 5P1P and also was not detected in lung microsomes from CYP2F2-KO mice (Shen et al., 2014) . The lack of response in the lungs at low doses in WT or at any dose in CYP2F2-KO mice indicates the central role of CYP2F2 metabolism in styrene lung toxicity.
Key event concordance is shown in Tables 8 and 9 . The data demonstrate that all the key events occur at doses less than or equal to those exhibiting lung toxicity and tumorigenicity in mice, and generally increase with increased styrene dose. In addition, all key events are absent in non-responsive rats or CYP2F2-KO or TG mouse strains.
Temporal association
Changes in gene expression occurred after a single inhalation 
NT
Males at 350 ppm had statistically significantly more lung tumors than control, but incidence was within the historical control range; regarded as "suggestive evidence" in report.
G. Cruzan et al. Regulatory Toxicology and Pharmacology 95 (2018) 17-28 exposure in WT mice. Changes in cell proliferation and cytotoxicity were found after a single inhalation exposure in WT mice and after 5 days in CD-1 mice. Hyperplasia was present as early as 5 days of exposure in CD-1 and WT mice exposed to 120 ppm styrene in the chronic mode of action bioassay, and was generally observed at 26, 52, 78 and 104 weeks in both mouse strains in this study . Increased lung tumors were found in CD-1 mice between 18 and 24 months. As noted above, no styrene-induced hyperplasia was observed at any time in KO or TG mice or in rats (Cruzan et al., 1998 . All key events occur at times prior to the formation of lung tumors, with hyperplasia evident at all times up to terminal sacrifice in the mode of action study.
Consistency and specificity
The incidence of key events, and absence thereof in CYP2F2 KO and CYP2F1 TG mice, is consistent with the incidence of toxicity, genomic responses and proliferative alterations in the lungs of CD-1 and WT mice exposed to styrene. The metabolism of styrene to ring-oxidized metabolites in lung is greatly reduced if CYP2F2 is inhibited or genetically removed (KO mice). All manifestations of this MOA are eliminated in the absence of CYP2F2 metabolism. The necessity of ringhydroxylation at the 4-position is supported by the lack of proliferative lesions in the lungs of B6C3F1 mice exposed to 4-methylstyrene (Conti et al., 1988; NTP, 1990) . Similar and consistent findings of lung toxicity and tumors in mice, but not rats, and that are associated CYP2F2 metabolism to ring-oxidized metabolites, are reported for ethylbenzene, naphthalene, cumene, coumarin, (Cruzan et al., 2009) , and fluensulfone (Strupp et al., 2012 (Strupp et al., , 2016 .
Biological plausibility
Based on 8 chronic rat studies and 5 chronic mouse studies, the only tumor of concern from animal studies is mouse lung tumors. Toxicity (proliferation, LDH release to BAL fluid and cell sloughing to the airway lumen) occurs in mouse lung, but not rat lung, from styrene exposure. Mice have large numbers of club cells in the terminal bronchioles of the lungs and these cells contain CYP2F2. Carlson established that styrene metabolism takes place in club cells, not alveolar cells. Cell proliferation following styrene exposure occurs in club cells, not alveolar cells (Hynes et al., 1999) . Hyperplasia occurs in club cells of mice exposed to styrene, and not alveolar cells. Administration of styrene to CYP2F2-KO mice produces no toxicity, no enhancement of gene expression, and no proliferative lesions.
Up-regulation of circadian clock genes was observed in WT mice exposed for 26 weeks to 120 ppm styrene . A late-stage disruption of the circadian network is consistent with organspecific cancers (Fu and Kettner, 2013) , and has been specifically associated with promotion of lung cancer in mice in which key circadian control genes (Per2 and Arntl) have been knocked out (Papagiannakopoulos et al., 2016) . These responses are also consistent with the observation that overall control of lung circadian cycle rhythms is localized in the club cells that are the primary target cell type for styrene mouse lung toxicity and tumorigenicity (Gibbs et al., 2009) .
Extensive data support the hypothesis that styrene induces mouse lung tumors through metabolism catalyzed by CYP2F2 to ring-oxidized compounds (Table 10 ).
Alternative MOA hypothesis
Styrene induces mouse lung tumors through a genotoxic action by styrene-7,8-oxide (SO).
Key event 1. MIE: metabolism to SO
SO is the primary metabolite of styrene in liver and lung of rats and mice, as well as in humans (Carlson, 2008) . A key consideration inconsistent with SO as the proximate metabolite responsible for systemic cancer outcomes, however, is the observation that blood concentrations of SO were much greater in Sprague-Dawley rats exposed to a nontumorigenic concentration of 1000 ppm styrene for 95 weeks (153 ng SO/ml blood in females, 185 ng SO/ml blood in males) (Cruzan et al., 1998 ), compared to a tumorigenic concentration of 40 ppm in CD-1 mice for 74 weeks (1.4 ng SO/ml blood in females, 2.5 ng SO/ml blood in males) (Cruzan et al., 2001 ). Thus, if it is assumed that systemicallydistributed SO is the proximate tumorigenic metabolite available to body tissues, a greater systemic tumor response would be expected in rats than in mice. These data indicate that distribution of blood SO is not a substantive contributor to lung or non-lung toxicity and tumorigenicity, an observation consistent with the findings in multiple mouse and rat chronic bioassays.
Key event 2. changes in gene expression indicative of mutagenic response
Exposure of CD-1 or WT mice to styrene by inhalation up to 120 ppm for 1 day to as long as 104 weeks, did not result in changes in gene expression indicative of a mutagenic or reactive oxygen species event (Andersen et al., , 2018 . Thus it is unlikely that either SO or a ring epoxide from styrene causes a mutagenic event.
Key event 3. genotoxic potential in mouse lung and non-lung tissues
In vitro genoxicity studies of SO generally are positive (IARC, 1994 (IARC, , 2002 . About half of the in vivo genotoxicity studies of SO are positive (Table 8) . However, in mouse lung, there was no increase in lung tumor initiation in A/J mice when styrene was administered by ip for 7 weeks followed by observation for 20 weeks (Brunnemann et al., 1992) . B6C3F1 mice were exposed to styrene via inhalation at 0, 125, 250, or 500 ppm for 14 days. 250 and 500 ppm styrene was lethal to 30-50% of the exposed mice. Chromosome damage was assayed in the lung of survivors. There was no increase in chromosomal aberrations in the styrene-exposed mice compared to the controls (Kligerman et al., 1993) . C57BL/6 mice were exposed to 0, 40, or 120 ppm styrene 6 h/ day 5 days/week for 1 or 4 weeks. Gene expression analysis indicated enhanced expression of genes related to cell cycle control and DNAreplication, but there was no indication of activation of p-53 dependent DNA damage pathways . There was no increase in lung tumors when SO was administered by gavage to mice (Lijinsky, 1986) .
Filser and Gelbke (2016) described toxicokinetic evaluations of blood styrene and SO concentrations resulting from styrene inhalation exposures in rats and humans. Due to saturation of metabolism of styrene to SO following inhalation or oral treatment, it was estimated that the maximum blood concentrations of SO cannot exceed 0.33 μg/ ml in rats and 0.036 μg/ml in humans. Interestingly, mice and rats administered high gavage doses of SO (500 mg/kg mice; 200 mg/kg rats; Filser et al., 1992) had brief peak SO blood concentrations of approximately 7 and 3.6 μg/ml, respectively. These doses were only tumorigenic to the site of contact in the stomach, indicating that even relatively high systemic SO concentrations are not carcinogenic. Compared to these maximum SO concentrations, exposure of volunteers for 2 h to 50 ppm styrene representative of occupational exposures resulted in blood SO concentrations ranging from 0.0003 to 0.0015 μg/ml (mean = 0.0008 μg/ml) (Johanson et al., 2000) . The volunteer SO concentrations were consistent with PBPK model estimates of end of shift SO concentrations following 75 ppm styrene exposures of 0.0048 μg/ml (Csanady et al., 2003) . Importantly, all of the animal and human blood SO concentrations, with exception of oral SO, are substantively less than SO concentrations necessary to elicit genotoxicity and mutations. Of the 39 clearly positive SO mutagenicity studies described by IARC (1994; , 35 had lowest effect level concentrations (LEC) of ≥24 μg/ml. The lowest SO LECs were 12, 3 and 1.2 μg/ml for in vitro human cell micronucleus formation, chromosomal aberrations and DNA strand breaks, respectively (IARC, 1994) , while 24 μg/ml was the LEC reported for in vitro gene mutations in human cells (IARC, 2002) . Overall, the very large disparity between maximally achievable blood concentrations compared to in vitro concentrations necessary to elicit genotoxicity and mutagenicity indicates the SO toxicokinetic data are inconsistent with the hypothesis that SO is a biologically plausible genotoxicant in animals or humans exposed to styrene.
Thus, while SO has genotoxic potential at high concentrations in in vitro systems, it appears to be rapidly metabolized in vivo and does not present a genotoxic risk to systemic tissues.
Key event 4. cytotoxicity/cell proliferation
A common hypothesis is that all non-neurotoxic effects of styrene are caused by SO. However, a significant body of evidence now indicates that SO is not the styrene metabolite responsible for cytotoxicity and cell proliferation leading to lung tumors in mice. First, the blood level of SO in rats exposed to 1000 ppm for 104 weeks (non-tumorigenic in rats) was 100 fold higher than the blood level of SO from 40 ppm styrene in mice (which caused lung tumors) (Cruzan et al., 1998 (Cruzan et al., , 2001 . Using whole lung explants, with styrene exposure to the trachea and perfusion from the pulmonary artery to the pulmonary vein, the production of SO from 1000 ppm in rat lungs was 8-fold higher than from mouse lungs exposed at 40 ppm (Hofmann et al., 2006) . Thus, based on blood or lung levels, rats exposed to high styrene exposures had considerably higher levels of SO without tumor formation compared to lower level exposures in mice that resulted in lung tumors. Short-term exposures to SO result in lung responses (LDH increases and cell sloughing to the airway lumen) (Gadberry et al., 1996; Cruzan et al., 2005 Cruzan et al., , 2012 . However, SO is not the proximate toxic metabolite. Further metabolism by CYP2F2 is required for toxicity/mitogenicity (Cruzan et al., 2012) . While intraperitoneally administered SO resulted in lung toxicity in WT mice, in the absence of CYP2F2 (CYP2F2 KO mice), SO was not toxic to mouse lung (Table 7) (Cruzan et al., 2012) . A chronic study of 275 and 550 mg/kg/day SO by gavage in mice did not result in increased lung tumors (Lijinsky, 1986) . The only increase was in forestomach tumors. Using a PBPK model, it is predicted that the level of SO in lungs of mice exposed to 550 mg/kg/day orally is as great or greater than from the metabolism of 40 ppm styrene (personal communication from C. Kirman using Sarangapani et al., 2002) . Thus direct administration of SO does not produce the lung tumors seen with administration of styrene, lending further support to the conclusion that SO is not the cause of the tumors.
Biological plausibility
The hypothesis that styrene induces mouse lung tumors due to a genotoxic mode of action mediated by its primary metabolite, SO, is not supported by data. There are no gene expression indications of a genotoxic response; there is no evidence of club cell toxicity/mitogenicity from SO in the absence of CYP2F2 metabolism, and direct administration of SO to mice did not result in lung tumors.
Summary of evidence for CYP2F2 MOA
Styrene induces lung tumors in mice, but not in rats. Because the blood and lung concentration of SO are much greater in rats at doses that do not cause tumors (1000 ppm) than at tumorigenic doses (40 ppm) in mice, it is unlikely that SO is the tumorigenic metabolite. Furthermore, there is no reduction in lung toxicity when styrene is administered to CYP2E1-KO mice. On the other hand, lung toxicity from styrene and SO is completely eliminated in CYP2F2-KO mice. CYP2F2-metabolites of styrene cause exfoliation of terminal bronchiolar cells, decreased production of CCSP (CC10), increased cell replication as measured by BrdU incorporation or KI-67 production, and enhanced expression of cell cycle genes and nuclear receptor genes.
CYP2F2 catalyzes aromatic ring-oxidation of styrene to metabolites such as 4-hydroxystyrene, 3,4-dihydroxystyrene, and 4-hydroxystyrene oxide. Inhibition of CYP2F2 or elimination of the enzyme results in a > 80% reduction in ring-oxidized metabolites from styrene or 4-hydroxystyrene. Thus, the lung toxicity of styrene exhibits a threshold response; i.e., some lower level of the ring-oxidized metabolites are present in CYP2F2-KO mice, but not in sufficient concentration to cause toxicity. A similar situation is present in rats where CYP2F4 is present at levels no more than 25% of that in mice (Baldwin et al., 2004) . No lung toxicity is seen from styrene exposure in rats, despite the expected levels of ring-oxidized metabolites similar to that in CYP2F2-KO mice, but much lower than in WT or CD-1 mice. The data supporting the CYP2F2 MOA are summarized in Table 10 .
Human Relevance of Styrene-Induced Mouse Lung Tumors
Mouse lung tumors result from longer-term internal tissue exposures to relatively high levels of ring-oxidized metabolites of styrene produced by CYP2F2. High levels of CYP2F2 are found only in nasal olfactory cells and pulmonary club cells in mice. Both tissues are susceptible to toxic effects from styrene. In the nose, there is degeneration of olfactory tissue, but no increased cell replication, while in the lung there is increased cell replication and eventually tumors.
The rat CYP2F isoform CYP2F4 is present to a lesser extent in rat lungs (Baldwin et al., 2004) . Metabolism of styrene in rat lung and mouse and rat liver by CYP2F and/or CYP2E1 is insufficient to cause toxic reactions in that these organs were not target organs for styrene toxicity or tumorigenicity in chronic mouse and rat bioassays exposed at an expected maximum tolerated dose of 160 ppm (mice) and 1000 ppm (rats) (Cruzan et al., 2002) . However, dose-limiting liver toxicity and increased mortality were observed in mice exposed to exposures ≥200 ppm styrene for 2 or 13 weeks (Cruzan et al., 1997) . CYP2F1 is expressed in human lung at lesser levels than mouse or rat lung (Baldwin et al., 2004) .
Styrene is readily metabolized to SO in human liver and most of it is further metabolized to styrene glycol or GSH conjugates in the same cells. However, SO is detected in the blood of workers exposed to styrene at much lower concentrations than those resulting in lung tumors in mice, and far lower than blood concentration that were not carcinogenic following high inhalation exposures in rats. The metabolism of styrene in human lung cells is much lower than in rat or mouse lung cells. For example, Carlson et al. (2000) found no formation of SO in 7 of 8 human lung tissue samples and very limited metabolism in the 8th sample. If one assumes that SO were the metabolite responsible for the mouse lung tumors, the level of SO in the lungs of human exposed to 200 ppm styrene (saturated metabolism) was calculated to be only 1/ 30 th the SO level in mice at lowest styrene concentration that produced increased lung tumors, (calculation based on PBPK model, Sarangapani et al., 2002) . Nakajima et al. (1994) infected HepG2 cells with recombinant vaccinia virus encoding for a number of different cytochromes, including 2E1 and 2F1. They reported the greatest formation of styrene glycol from styrene in cells infected with 2F1, about twice as much as from 2E1. Using PBPK analysis, Csanady et al. (2003) estimated that the Vmax for styrene oxidation to SO by the mouse was about 350 times faster than the rate estimated by Nakajima et al. (1994) . Using a BEAS2B lung cell line that overexpresses CYP2F1, Carlson (2008) was not able to find any styrene metabolism by CYP2F1. In humanized mice (2F2KO, 2F1TG), no lung increase in BrdU incorporation was found during 5 days of exposure to 200 mg/kg styrene, compared to a 5-10-fold increase in normal mice (Cruzan et al., 2013) . Thus, styrene is metabolized to no more than a minute amount in human lung.
Effect of styrene in CYP2F2(−/−), (CYP2F1, CYP2A13, CYP2B1-transgenic) mice
CD-1 and C57BL/6 (designated as wild-type, WT) mice are susceptible to toxicity from styrene metabolites produced by CYP2F2. These effects do not occur when CYP2F2 is absent. Because these strains of mice are susceptible to toxicity when sufficient CYP2F metabolites are present, a genetically modified strain was created in which the CYP2F2 gene was removed and a transgene containing the human CYP2F1 was inserted. This transgenic mouse had three human genes -CYP2F1, 2A13 and 2B6). These TG mice produce no CYP2F2, but do have measurable amounts of the CYP2F1 protein in the lung (Wei et al., 2012; Jia et al., 2014; Li et al., 2017) . Isolated human CYP2F1 does metabolize 3-methylindole and naphthalene. Metabolism of both these compounds have been shown to occur in these TG mice (Cruzan et al., 2013; Li et al., 2017) . Thus these TG mice make a good model for assessing expected results of styrene inhalation in humans. Styrene administered at 200 mg/kg/day by ip for 5 days did not increase the incorporation of BrdU into the terminal bronchiolar cells of TG mice (Table 11) (Cruzan et al., 2013) . In addition, inhalation of 40 or 120 ppm styrene 6 h/day 5 days/week for 1 day or for 1, 4 or 26 weeks) did not enhance the expression of genes in the lungs of TG mice . The lack of short-term styrene-induced toxicity and enhanced gene expression in TG mice relative to WT controls also was consistent with an absence of preneoplastic hyperplasia (and tumors) in TG mice exposed to120 ppm for up to 104 weeks . TG mice are susceptible to toxic effects similar to those in the WT mice if sufficient ring-oxidized metabolites are present. Administration of 105 mg/kg/day 4-hydroxystyrene by ip for 5 days to TG mice caused a mild increase in BrdU incorporation into the terminal bronchiolar cells. The increase was less than seen with styrene in WT mice. In contrast, 5 days of administration of 200 mg/kg/day ip of the vinylgroup oxidized metabolite of styrene, styrene oxide, did not result in any detectable increase in BrdU incorporation in the TG mice (Cruzan et al., 2013) . The absence of lung toxicity in TG mice administered styrene or styrene oxide indicates that ring-oxidized metabolite(s) are not formed from either of these precursors in TG mice at concentrations sufficient to induce toxicity, even when administered at relatively high 200 mg/kg/day ip doses (Cruzan et al., 2013) . Furthermore, there are insufficient concentrations of these metabolites to cause enhanced gene expression in TG mice exposed to up to 120 ppm styrene .
Thus, styrene-induced mouse lung tumors do not support a conclusion of human carcinogenic hazard from styrene. The NTP (2011), in its 12th Report on Carcinogens, classified styrene as "reasonably anticipated to be a human carcinogen". In a subsequent review of the overall styrene and SO data, the NAS also concluded that styrene was "reasonably anticipated to be a human carcinogen" based on "credible but limited evidence" in epidemiology studies, sufficient evidence of carcinogenicity in animals, and convincing mode of action data indicating styrene is genotoxic in humans. However, the NAS conclusion is inconsistent with updates and refinements of the styrene epidemiology and mode of action datasets that were not available to NAS at the time of its review.
The NAS (2014) specifically concluded that there was "credible but limited in epidemiology studies that styrene was a risk factor for lymphohematopoietic, kidney, pancreatic and esophageal cancers". They indicated that evidence of a lung cancer risk was supported from mouse lung tumorigenicity following chronic inhalation and oral styrene administration. However, since the release of the NAS report the key cohort data used to support the NAS conclusions have been updated, and those updated datasets, which included the highest exposed styrene workers in the reinforced plastics industry, have been reviewed and subjected to meta-analysis evaluations in Collins and Delzell (2018) . That systematic review concluded that there is "no strong and consistent indication of a causal association between styrene and NHL, subtypes of NHL, all leukemia, subtypes of leukemia or cancers of the esophagus, pancreas, lung, kidney or other sites." Collins and Delzell (2018) reviewed epidemiology data published through June 2017 and conducted meta-analyses both of all identified styrene studies and those limited to the reinforced plastics industry. The meta-relative risks for all studies were: NHL: 1.14 (95% confidence interval ( . When meta-analyses were restricted to studies of workers in the higher exposed reinforced plastics industries, the meta-relative risks were similar to all studies with the exception higher risks in lung of 1.26 (1.16-1.36) and kidney of 1.13 (1.01-1.27). In part because a lack of consistency in exposure-response trends, Collins and Delzell G. Cruzan et al. Regulatory Toxicology and Pharmacology 95 (2018) 17-28 (2018) concluded that confounding by smoking likely explained some or all of the increased meta-relative risk of lung cancer in the updated reinforced plastics industry workers. The meta-analysis of kidney cancer in the highest exposed worker cohorts indicated only a weak association for this cancer outcome, and none of the updated studies controlled for lifestyle factors such as smoking, obesity and other occupational exposures that have been associated with kidney cancer. The recent Collins and Delzell (2018) analyses provide updated and refined epidemiology analyses that directly counter the NAS conclusion that the styrene epidemiology data offer limited but credible evidence that potential target organs exist in humans beyond the single cancer target identified in multiple rodent bioassays (mouse lung). Importantly, however, and based on its interpretation of the epidemiology data available at the time of its review, the NAS extended those conclusions by calling for further mode of action investigations in animals and potentially humans to further evaluate the biological plausibility of styrene tumorigenicity. NAS specifically noted that until collection of "comprehensive information on bioactivation and detoxification rates in specific target organs" was completed, the possibility of styrene human carcinogenicity at these sites could not be plausibly excluded. The recent epidemiology updates and meta-analysis (Collins and Delzell, 2018) , however, indicate that styrene-induced cancer outcomes in any of the organs identified in the NAS review are not plausible. The weak association with kidney cancer does not justify further mode of action investigations given the likelihood of non-styrene factors that may have influenced that finding. It is important to note that, consistent with findings of Collins et al. (2013) and Collins and Delzell (2018) , the NAS concluded that the epidemiology evidence offered no credible evidence of styrene as a lung carcinogen. However, the NAS concluded that there was sufficient evidence of lung cancer in mice based on positive responses by two routes of administration (inhalation and oral), and that mouse lung specific tumors could not be excluded as human relevant based on available mode of action information.
The NAS call for additional mode of action data in target organs other than lung is also inconsistent with the significant amount of mode of action data (some after the NAS review) demonstrating that mouse specific lung toxicity and carcinogenicity is attributable to lung metabolism of styrene and/or SO to ring-oxidized metabolite(s) by CYP2F2 specifically enriched in mouse terminal bronchiolar club cells (see above). In addition, the NAS recommendation for such studies is inconsistent with the fact that styrene is carcinogenic only in mouse lung despite being tested in 8 rat and 5 mouse chronic bioassay using multiple rodent strains and inhalation and oral routes of exposures. The absence of tumor findings in any organ other than lung in multiple rodent chronic bioassays is consistent with the recent epidemiology updates and meta-analyses indicating styrene is not carcinogenic in humans.
The NAS suggestion of the possible human relevance of styreneinduced mouse lung tumors places significant weight on the observation that both rodents and humans share SO as a common and hypothesized genotoxic metabolite in blood of styrene exposed individuals, and SO systemic distribution could account for the multiple target organs suggested from the limited epidemiological evidence at the time of the NAS review. As described above, not only are the SO blood concentrations resulting from inhalation or oral treatments well below SO concentrations eliciting genotoxic responses in vitro, they are also inconsistent with absence of tumor responses in any organ other than lung. The highest blood concentrations of SO are observed in mice and rats orally administered 500 and 200 mg/kg SO doses (7 and 3.6 μg/ml, respectively), yet neither of these blood concentrations induced systemic tumorigenic responses in these species. Thus, the overall toxicokinetics of SO following either styrene or SO administration are not consistent with the hypothesis that SO could be a driver of multiple organ tumor responses observed in the limited epidemiology evidence reviewed by NAS.
The NAS also speculated that an SO genotoxic mode of action was plausible based on reports of SO DNA adducts resulting from styrene treatment. However, this hypothesis is not consistent with the observation that rats and mice exposed to 160 ppm styrene for 6 h exhibited very low levels of DNA adducts in both liver and lung (Boogaard et al., 2000) . In addition the covalent binding index in these tissues was inconsistent with chemicals operating by a genotoxic mode of action. Finally, the NAS expressed concern that mode of action studies conducted in CYP2F2 KO and CYP2F1 TG mice might have resulted in an absence of toxicity outcomes because of the study routes of exposure (oral and/or intraperitoneal). However, a recent chronic inhalation study conducted in WT and CYP2F2KO mice at 120 ppm, 6 h/day, 5 days/week for 104 weeks found no evidence of styrene lung toxicity or tumorigenicity in KO mice . These results indicate that styrene route of administration is not a determinant of the attenuation of lung toxicity in CYP2F2 KO mice. The NAS also expressed a concern that, although expression of various CYP styrene-activating enzymes was equivalent between WT and KO mice (Li et al., 2011) , the CYP2F2 KO might have had an uncharacterized compensatory overexpression of detoxification enzymes such as epoxide hydrolase or glutathione transferase(s) that could have been a determinant of the lack of styrene toxicity in these mice. However, there was no increase in expression of epoxide hydrolase or glutathione transferase genes in CYP2F2 KO mice compared to WT or CD-1 mice (Andersen et al., 2018) at any interval during the chronic inhalation study . Thus, these results are inconsistent with speculation that enhanced detoxification of SO in CYP2F2 KO mice might have contributed to the complete attenuation of lung toxicity in this mouse strain. In contrast, however, Shen et al. (2014) demonstrated that the formation of ring-oxidized styrene metabolites (2-, 3-, and 4-vinylphenol) was completely attenuated in the KO mice lung microsomes, consistent with the hypothesized key role of CYP2F2 in formation ring-oxidized lung toxic styrene metabolites. Importantly, Shen et al. (2014) also demonstrated SO generation was highly active in CYP2F2-KO mice in that liver and lung microsomal formation of styrene glycol (V max /K m ) was similar to WT mice. These data indicate that the attenuation of styrene lung toxicity in CYP2F2-KO mice was not due reduced SO generation.
Evidence of lung tumors in styrene-exposed workers
A systematic review of all the epidemiologic reports on the relationship of styrene exposure in humans has recently been published (Collins and Delzell, 2018) . In addition to considering all the studies, they performed meta-analyses of all tumors suggested as increased by styrene exposure. There was no increase in lymphohematopoietic cancers (leukemias, lymphomas), pancreatic, esophageal, lung or kidney cancers when all studies were included. When only studies of reinforced plastics workers were considered, there was slight increase in kidney cancer (meta-relative risk = 1.13 (95% CI = 1.01-1.27) and for lung cancer (risk = 1.26 (95% CI = 1.16-1.36). One study found an inverse dose-response of lung cancer to styrene exposure (Collins et al., 2013) . A nested case-control study (Wong, 1990) concluded that smoking was the cause of increased lung cancer in this cohort.
Lack of site concordance
In some cases, increase in cancer occurs in different organs in different species. Therefore, it is possible that styrene could cause a different cancer in humans than the lung tumors seen in mice. Data in rats do not support a hypothesis that styrene causes cancer in different tissues in different species since no tissues had increased cancer incidence from even very high styrene exposures, up to 2000 mg/kg/day by gavage or 1000 ppm by inhalation (Cruzan et al., 1998) .
A primary concern in human studies has been increased total lymphohematopoietic (LH) cancers or in specific types of LH cancer. No increase in LH cancers, Non-Hodgkin lymphoma or leukemia was found in the US cohort studies (Collins et al., 2013; Ruder et al., 2004) or in the UK cohort (Coggon et al., 2015) . An increase in leukemia was found among Danish potential RPC workers with less than one year of exposure, but not more than one year, or among those hired before 1960 . In the update of this study, there was no increase in leukemia or lymphoma (Christensen et al., 2017) . In the multicountry EU cohort (of which Coggon and Kolstad were a part), there was an increased risk of malignant lymphoma based on average exposure, but not cumulative exposure (Kogevinas et al., 1994) . Interpretations of this dataset are highly variable. Some have interpreted this dataset to provide limited evidence of carcinogenicity from styrene in humans (NTP, 2011; NAS, 2014) , while others concluded there was no evidence of carcinogenicity from these studies (Boffetta et al., 2009) .
In a systematic review of the epidemiologic studies (Collins and Delzell, 2018) performed meta-analysis of several tumor types. They performed meta-analysis of risk from data in 13 studies of workers in reinforced plastics, synthetic rubber and monomer/polymer production. Meta-relative risks for all studies were 1.14 (95% confidence interval (CI), 0.91-1.43) for NHL, 0.98 (95% CI, 0.87-1.09) for all leukemia, 0.97 (95% CI, 0.82-1.15) for lymphoid leukemia, 1.06 (95% CI, 0.80-1.39) for myeloid leukemia, 1.03 (95% CI, 0.92-1.15) for esophageal cancer, 1.02 (95% CI, 0.93-1.12) for pancreatic cancer, 1.09 (95% CI, 0.95-1.24) for lung cancer and 1.10 (95% CI, 0.99-1.22) for kidney cancer; the risk for cancer from styrene exposure was not statistically increased for of these cancer types.
Conclusion
Strong evidence has been developed that styrene (and similar compounds) are metabolized to ring-oxidized compounds in mouse lung club cells (Table 10 ). When produced in sufficient quantity, these metabolites cause tissue responses in mouse lungs with enhanced gene expression. These data sets support a molecular initiating event for styrene of direct mitogenicity from mouse-specific CYP2F2-mediated metabolites that appear to activate Nr4a signaling. Longer-term modifying factors include down-regulation of Nr4a genes and shifts in both circadian clock transcription factors (TFs) and other TFs, linking circadian clock to cellular metabolism. No gene expression changes indicative of cytotoxicity or activation of p53-mediated DNA-damage pathways was found at any time of exposure. In the absence of CYP2F2 metabolism, or CYP2F1 metabolism in TG mice, neither styrene nor SO produce cytotoxic or proliferative changes in lung (styrene includes 104 week exposure to 120 ppm styrene). The lack of SO toxicity in both the KO and TG mouse strains supports a conclusion that SO is not the proximate metabolite accounting for the lung toxicity and tumorigenicity of styrene in mice. Importantly, the mode of action evidence also supports a conclusion that SO formed in humans primarily by CYP2E1 is not subsequently metabolized by CYP2F1 to ring-oxidized metabolite(s) in amounts sufficient to present a lung toxicity or tumorigenicity risk.
The role of CYP2F2 metabolism as an essential mode of action gateway event responsible for mouse lung toxicity is consistent with toxicity and mode of action data in rats. Rats have less CYP2F (2F4) than mice and therefore produce less ring-oxidized metabolites. No cytotoxic, proliferative or tumorigenic changes are found in the lungs of rats exposed to styrene, even up to 1000 ppm for 2 years.
Overall, the animal MoA data unequivocally indicate that lung tumors are unique to the mouse due to mouse-specific metabolism of styrene by CYP2F2 (Fig. 1) . Thus, the MoA indicates styrene-induced mouse lung tumors are likely qualitatively, or possibly quantitatively, not relevant to humans.
